The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.
Thermo Fisher Scientific, Inc. (TMO)
Common Stock · Currency in USD · XNYS
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Company Info
SIC3829
Composite FIGIBBG000BVDLH9
CIK0000097745
IPOJun 1, 1972
Sectormeasuring & controlling devices, nec
Highlights
Market Cap$182.57B
EPS$17.12
P/E Ratio28.16
Revenue$43.95B
Gross Profit$44.49B
Net Income$6.48B
Employees125,000
WSO371,484,244
Phone(781) 622-1000
Websitehttps://www.thermofisher.com
Related Tickers
WST
West Pharmaceutical Services, Inc.
$253.88 0.00%
MEDP
Medpace Holdings, Inc. Common Stock
$498.34 0.00%
MCK
McKesson Corporation
$886.00 0.00%
AMN
AMN Healthcare Services
$18.20 0.00%
BIO
Bio-Rad Laboratories, Inc.Class A
$279.99 0.00%
A
Agilent Technologies Inc.
$115.48 0.00%
DHR
Danaher Corporation
$191.12 0.00%
QGEN
QIAGEN N.V.
$41.03 0.00%
BIO.B
Bio-Rad Laboratories, Inc. Class B
$278.25 0.00%
HAE
Haemonetics Corporation
$56.83 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Thermo Fisher Scientific, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Thermo Fisher Scientific, Inc. (TMO) has returned -15.19% so far this year and 17.64% over the past 12 months. Looking at the last ten years, TMO has achieved an annualized return of 13.20%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
TMO
1M-2.33%
6M-8.99%
YTD-15.19%
1Y17.64%
5Y0.55%
10Y13.20%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Thermo Fisher Scientific, Inc. (TMO) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.15% | -9.51% | -4.00% | -0.98% | ||||||||
| 2025 | 15.14% | -10.82% | -6.28% | -13.43% | -5.41% | 1.33% | 15.11% | 6.87% | -0.88% | 16.51% | 4.82% | -2.59% |
| 2024 | 1.78% | 5.17% | 2.95% | -2.12% | -0.33% | -2.88% | 10.82% | -0.22% | 1.16% | -11.88% | -3.70% | -1.60% |
| 2023 | 3.08% | -7.56% | 6.87% | -2.57% | -8.55% | 1.68% | 5.65% | 1.93% | -10.17% | -11.59% | 11.37% | 8.13% |
| 2022 | -12.32% | -7.53% | 8.45% | -6.64% | 3.40% | -4.61% | 10.01% | -8.21% | -6.50% | 0.23% | 8.46% | -2.99% |
| 2021 | 8.67% | -12.92% | 0.48% | 1.95% | -0.48% | 8.02% | 6.76% | 2.37% | 3.36% | 10.95% | 0.08% | 5.13% |
| 2020 | -3.93% | -8.21% | -2.55% | 21.04% | 5.69% | 4.12% | 13.80% | 2.57% | 2.17% | 6.09% | -2.89% | -0.90% |
| 2019 | 11.74% | 5.79% | 4.87% | 0.84% | -3.68% | 9.46% | -7.17% | 2.72% | 2.40% | 3.50% | 2.93% | 2.92% |
| 2018 | 17.46% | -6.95% | -1.04% | 2.25% | -1.03% | -1.36% | 13.99% | 2.11% | 2.17% | -4.99% | 6.41% | -11.77% |
| 2017 | 7.02% | 3.55% | -3.68% | 7.64% | 3.86% | 0.97% | 0.11% | 6.23% | 0.52% | 2.12% | -1.22% | -1.50% |
| 2016 | 2.88% | 4.66% | -2.33% | 7.37% | -4.13% | 4.20% | -6.91% | -5.33% | 0.45% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Thermo Fisher Scientific, Inc. (TMO) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of TMO compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Thermo Fisher Scientific, Inc. volatility is 1.86%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 110.34B | 97.32B | 98.73B | 97.15B | 95.12B | 69.05B | 58.38B | 56.23B | 56.67B | 45.91B | 40.89B | 42.85B | 31.86B | 27.44B | 26.83B |
| Temporary Equity (USD) | 122.00M | 120.00M | 118.00M | 116.00M | 122.00M | - | - | - | - | - | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 53.41B | 49.58B | 46.74B | 43.98B | 40.79B | 34.51B | 29.68B | 27.59B | 25.41B | 21.54B | 21.35B | 20.55B | 16.86B | 15.46B | 15.04B |
| Equity Attributable To Noncontrolling Interest (USD) | 7.00M | -33.00M | -11.00M | 54.00M | 62.00M | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 53.42B | 49.55B | 46.72B | 44.03B | 40.86B | 34.51B | 29.68B | 27.59B | 25.41B | 21.54B | 21.35B | 20.55B | 16.86B | 15.46B | 15.04B |
| Redeemable Noncontrolling Interest (USD) | 122.00M | 120.00M | 118.00M | 116.00M | 122.00M | - | - | - | - | - | - | - | - | - | - |
| Other Non-current Liabilities (USD) | 2.57B | 3.37B | 3.26B | 1.83B | 6.16B | 2.51B | 4.76B | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | 39.17B | 31.07B | 34.73B | 34.28B | 34.67B | 21.74B | 17.75B | - | - | - | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 41.74B | 34.44B | 37.99B | 36.11B | 40.83B | 24.24B | 22.51B | 22.50B | 24.21B | 19.50B | 15.39B | 16.95B | 11.88B | 9.89B | 8.68B |
| Other Current Liabilities (USD) | 9.57B | 8.27B | 9.54B | 11.53B | 8.14B | 6.21B | 3.27B | 3.55B | 4.70B | 3.23B | 2.73B | 3.86B | 2.00B | 1.06B | 2.16B |
| Wages (USD) | 2.00B | 1.99B | 1.60B | 2.10B | 2.43B | 1.92B | 1.01B | 982.00M | 918.00M | 708.70M | 598.20M | 668.90M | 432.00M | 388.00M | 327.20M |
| Accounts Payable (USD) | 3.62B | 3.08B | 2.87B | 3.38B | 2.87B | 2.18B | 1.92B | 1.62B | 1.43B | 926.20M | 822.20M | 820.70M | 691.50M | 641.40M | 628.70M |
| Current Liabilities (USD) | 15.19B | 13.33B | 14.01B | 17.01B | 13.44B | 10.30B | 6.20B | 6.15B | 7.05B | 4.87B | 4.15B | 5.35B | 3.13B | 2.09B | 3.11B |
| Liabilities (USD) | 56.93B | 47.77B | 52.00B | 53.12B | 54.27B | 34.55B | 28.71B | 28.65B | 31.26B | 24.37B | 19.54B | 22.30B | 15.01B | 11.98B | 11.80B |
| Other Non-current Assets (USD) | 55.23B | 50.35B | 48.02B | 45.20B | 46.56B | 28.50B | 27.73B | 26.46B | 26.52B | 22.34B | 19.94B | 19.78B | 13.14B | 13.08B | 12.54B |
| Intangible Assets (USD) | 15.84B | 15.53B | 16.67B | 17.44B | 20.11B | 12.69B | 14.01B | 14.98B | 16.68B | 13.97B | 12.76B | 14.11B | 7.07B | 7.80B | 7.82B |
| Fixed Assets (USD) | 10.57B | 9.31B | 9.45B | 9.28B | 8.33B | 5.91B | 4.75B | 4.17B | 4.05B | 2.58B | 2.45B | 2.43B | 1.77B | 1.73B | 1.66B |
| Noncurrent Assets (USD) | 81.64B | 75.18B | 74.14B | 71.93B | 75.01B | 47.10B | 46.49B | 45.61B | 47.25B | 38.89B | 35.15B | 36.31B | 21.98B | 22.61B | 22.01B |
| Other Current Assets (USD) | 23.28B | 17.16B | 19.50B | 19.60B | 15.06B | 17.93B | 8.52B | 7.62B | 6.45B | 4.81B | 3.75B | 4.68B | 8.39B | 3.39B | 3.47B |
| Inventory (USD) | 5.43B | 4.98B | 5.09B | 5.63B | 5.05B | 4.03B | 3.37B | 3.01B | 2.97B | 2.21B | 1.99B | 1.86B | 1.49B | 1.44B | 1.36B |
| Current Assets (USD) | 28.71B | 22.14B | 24.59B | 25.23B | 20.11B | 21.96B | 11.89B | 10.63B | 9.42B | 7.02B | 5.74B | 6.54B | 9.88B | 4.83B | 4.82B |
| Assets (USD) | 110.34B | 97.32B | 98.73B | 97.15B | 95.12B | 69.05B | 58.38B | 56.23B | 56.67B | 45.91B | 40.89B | 42.85B | 31.86B | 27.44B | 26.83B |
News and Insights
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.
The global oncology biomarkers market is projected to grow from $17.3 billion in 2025 to $33.63 billion by 2030, with a CAGR of 14.3%. Growth is driven by rising cancer incidence, personalized oncology therapies, AI-driven biomarker discovery, liquid biopsy adoption, and early cancer detection focus. Key players include Roche, Novartis, and Thermo Fisher Scientific.
Major M&A activity continues with Estée Lauder in merger discussions with Puig ($40B), KKR acquiring Nothing Bundt Cakes ($2B+), and Amazon acquiring robotics firm Fauna. Other significant deals include Corebridge-Equitable Holdings merger ($22B), Merck's acquisition of Terns Pharmaceuticals ($6.7B), and Abbott closing its Exact Sciences deal ($21B). Several companies filed for bankruptcy including 23andMe and Applebee's franchisee NRPF.
The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.
The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
The global Respiratory Disease Testing Market is projected to grow from USD 5.99 billion in 2025 to USD 9.32 billion by 2032, with a CAGR of 6.50%. Growth is driven by advances in molecular diagnostics, digital imaging, telemedicine, and strategic partnerships. However, 2025 tariff revisions have impacted supply chains, prompting organizations to adopt flexible sourcing strategies and invest in local production capabilities.
The global genomics services market is expected to grow from USD 7.94 billion in 2025 to USD 25.18 billion by 2035, with a CAGR of 11.8%. Growth is driven by increasing genetic disorder prevalence, government-funded precision medicine initiatives, and rising adoption of NGS-based diagnostics. The U.S. market alone is projected to reach USD 10.04 billion by 2035. Next-generation sequencing dominates with 38.42% market share, while Asia Pacific shows the fastest growth at 13.84% CAGR.
The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.